TG Therapeutics Inc (TGTX)

[stockguard]

Off Topic:

Forgot to add this in my post to you.

10/01/2018
Cantor Fitzgerald. Analyst Elemer Piros maintained a Buy rating on Corbus Pharmaceuticals today and set a price target of $36. The company’s shares opened today at $7.68.

Piros said:

“We rate Corbus Pharmaceuticals Overweight. CRBP focuses on the development of a synthetic cannabinoid receptor type 2 (CB2) agonist, lenabasum (JBT-101), for the treatment of rare inflammatory and fibrotic diseases. The company has completed three successful Phase 2 clinical trials in patients with cystic fibrosis (CF) and diffuse cutaneous systemic sclerosis (dcSSc) and dermatomyositis (DM). Valuation Summary We value Corbus based on a risk-adjusted NPV of future cash flows associated with lenabasum. Our 12-month price target is $36/share.”